EGM
KPTI icon

Engineers Gate Manager’s Karyopharm Therapeutics KPTI Stock Holding History

Engineers Gate Manager’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$332K Sell
33,966
-78,466
-70% -$681K ﹤0.01% 1726
2026
Q1 		$626K Buy
+112,432
New +$857K 0.01% 1276
2025
Q1 		– Sell
-1,913
Closed -$19.4K – 2374
2024
Q4 		$19.4K Sell
1,913
-1,296
-40% -$15.7K ﹤0.01% 2159
2024
Q3 		$40K Buy
3,209
+1,296
+68% +$16.1K ﹤0.01% 1992
2024
Q2 		$24.9K Hold
1,913
– – ﹤0.01% 1844
2024
Q1 		$43.3K Hold
1,913
– – ﹤0.01% 1812
2023
Q4 		$24.8K Sell
1,913
-684
-26% -$9.22K ﹤0.01% 1892
2023
Q3 		$52.2K Buy
2,597
+1,669
+180% +$37.5K ﹤0.01% 1652
2023
Q2 		$24.9K Buy
+928
New +$40K ﹤0.01% 1659
2023
Q1 		– Sell
-3,303
Closed -$168K – 1834
2022
Q4 		$168K Buy
3,303
+1,250
+61% +$86.6K 0.01% 1417
2022
Q3 		$168K Sell
2,053
-1,209
-37% -$90.3K 0.01% 1363
2022
Q2 		$221K Buy
+3,262
New +$299K 0.01% 1590
2022
Q1 		– Sell
-1,880
Closed -$181K – 2101
2021
Q4 		$181K Sell
1,880
-2,173
-54% -$217K 0.01% 1689
2021
Q3 		$354K Buy
4,053
+3,054
+306% +$317K 0.02% 1097
2021
Q2 		$155K Sell
999
-3,555
-78% -$516K 0.01% 1448
2021
Q1 		$719K Buy
4,554
+3,050
+203% +$643K 0.04% 761
2020
Q4 		$349K Sell
1,504
-1,007
-40% -$233K 0.02% 1200
2020
Q3 		$550K Buy
2,511
+1,643
+189% +$402K 0.03% 947
2020
Q2 		$247K Buy
+868
New +$257K 0.01% 1322

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Engineers Gate Manager's KPTI Position: Q2 2026 in Review

Engineers Gate Manager reduced its Karyopharm Therapeutics (KPTI) stake by 70% in Q2 2026, selling an estimated $681K and leaving 33,966 shares worth $332K. The position accounts for ﹤0.01% of the portfolio, ranked #1726.

Engineers Gate Manager first reported a position in KPTI in Q2 2020 and has held it in 19 quarters since. The position peaked at $719K in Q1 2021. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Engineers Gate Manager held 33,966 shares of Karyopharm Therapeutics worth $332K as of Q2 2026.
  • Engineers Gate Manager sold 78,466 Karyopharm Therapeutics shares in Q2 2026, an estimated $681K.
  • Karyopharm Therapeutics made up ﹤0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #1726 holding.
  • Engineers Gate Manager first reported a position in Karyopharm Therapeutics in Q2 2020 and has held it in 19 quarters since.
  • Engineers Gate Manager's Karyopharm Therapeutics position peaked at $719K in Q1 2021.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.